Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients
Guiding principles of sublingual immunotherapy for allergic rhinitis in Japanese patients
复制标题
DOI：
10.1016/j.anl.2015.08.015
复制
发表时间：
2016-02-01
影响因子：
1.7
通讯作者：
Fujieda, Shigeharu
中科院分区：
文献类型：
--
作者：
Masuyama, Keisuke;Goto, Minoru;Fujieda, Shigeharu
目的：舌下免疫疗法（SLIT）为变应性鼻炎（AR）的治疗提供了实际优势。基于对科学文献的回顾，我们提出的建议作为指导原则，管理SLIT safety.Methods：临床问题有关SLIT的准备。从PubMed、科克伦图书馆和Japana Centra Revuo Medicina中检索了2003年1月至2012年12月期间发表的文献。对合格的研究进行了分析，并对结果进行了评价、合并和编码。我们回答了17个临床问题，并在此基础上提出了循证建议。结果：舌下免疫治疗改善了症状（例如，生活质量[QOL]）和季节性AR和常年性AR的药物评分降低。大多数SLIT引起的不良反应是局部口服反应，尽管偶尔报告全身不良反应，如胃肠道症状、荨麻疹和哮喘。SLIT尚未报告致死性速发过敏反应。SLIT持续3-4年后，其效果持续很长时间后discovery.Conclusion：AR的正确诊断和充分的知情同意，患者开始SLIT之前，需要。舌下免疫治疗应持续3年或更长时间。在过敏原疫苗上调期间SLIT的初始给药和患者的一般状况对于SLIT的安全性能至关重要。(C)2015爱思唯尔爱尔兰有限公司版权所有。
Objective: Sublingual immunotherapy (SLIT) appears to offer practical advantages for the treatment of allergic rhinitis (AR). Based on a review of the scientific literature, we present recommendations as guiding principles to administer SLIT safely.Methods: Clinical questions concerning SLIT were prepared. Literature published between January 2003 and December 2012 was searched from PubMed, the Cochrane Library, and Japana Centra Revuo Medicina. Qualified studies were analyzed and the results were evaluated, consolidated, and codified. We answered 17 clinical questions and, based on this, presented evidence-based recommendations.Results: Sublingual immunotherapy improved symptoms (e.g., quality of life [QOL]) and reduced medication scores in seasonal AR and perennial AR. Most SLIT-induced adverse effects were local oral reactions, although systemic adverse effects such as gastrointestinal symptoms, urticaria, and asthma are occasionally reported. There have been no reports of lethal anaphylactic reactions by SLIT. When SLIT is continued for 3-4 years, its effect persists long after discontinuation.Conclusion: A correct diagnosis of AR and sufficient informed consent from patients are required before initiating SLIT. Sublingual immunotherapy should be continued for 3 years or longer. The initial administration of SLIT during the uptitration of an allergen vaccine and the general condition of patients are critical for the safe performance of SLIT. (C) 2015 Elsevier Ireland Ltd. All rights reserved.